SAN ANTONIO, Texas--(BUSINESS WIRE)--A new economic study found that adding CyPath® Lung, bioAffinity Technologies’ noninvasive test for detection of early-stage lung cancer, to the standard of care ...

SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) today released a study of a complex clinical case in which CyPath® Lung’s real-time assessment of the lung ...

There are roughly 225,000 new cases of lung cancer every year in the United States. Early diagnosis and treatment play a large role in improving outcomes. A recently developed nasal swab test could ...

Add Yahoo as a preferred source to see more of our stories on Google. For most patients, the diagnosis and surgical treatment of an early-stage cancerous lung tumor is a drawn-out process. “At about ...

CyPath® Lung test supported recommendation for surveillance strategy, rather than subjecting elderly patient to an invasive, risky and costly biopsy procedure Despite a suspicious nodule during a ...

A chest X-ray is often the first test as part of the diagnostic process for non-small cell lung cancer (NSCLC). It can sometimes show a mass, plus its size and location. A chest X-ray cannot diagnose ...

Lung cancer is the leading cause of death from cancer. It kills more people in the U.S. than breast, prostate, and colon ...

Biodesix, Inc. announced a new study published in CHEST Pulmonary Journal reaffirming the effectiveness of its Nodify CDT® blood-based lung nodule test, which assesses seven autoantibodies linked to ...

SAN ANTONIO - bioAffinity Technologies, Inc. (NASDAQ:BIAF) announced a study with Brooke Army Medical Center to validate its CyPath Lung diagnostic test using sputum samples collected through tracheal ...